Beyond PD-L1–positive disease, pembrolizumab also carries tumor-agnostic approvals for MSI-H/dMMR and TMB-high tumors, providing an additional therapeutic pathway for this rare molecular subset of cervical cancers. This evidence concerns the gene CD274 and neoplasm.